Impact of prophylactic mastectomy in BRCA1/2 mutation carriers

Breast Care

Volumn 9, Issue 6, 2014, Pages 385-389

  Rhiem, Kerstin ^a   Schmutzler, Rita ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

BRCA1; BRCA2; High risk genes; Prophylactic mastectomy

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CARRIER PROTEIN;

BREAST CANCER; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; DECISION MAKING; GENE MUTATION; GENETIC SCREENING; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MASTECTOMY; PRIORITY JOURNAL; PROPHYLACTIC SURGICAL PROCEDURE; PROTEIN POLYMORPHISM; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION;

EID: 84921345224     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000369592     Document Type: Review

References (27)

1. King T, Sakr R, Patil S, et al.: Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol 2011; 29: 2158-2164.
2. Mavaddat N, Peock S, Frost D, et al.; EMBRACE: Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 2013; 105: 812-822.
3. Rebbeck TR, Friebel T, Lynch HT, et al.: Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004; 22: 1055-1062.
4. Domchek SM, Friebel TM, Singer CF, et al.: Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010; 304: 967-975.
5. Meijers-Heijboer H, van Geel B, van Putten WL, et al.: Breast cancer after prophylactic bilateral mastectomy in women with BRCA1 and BRCA2 mutation. N Engl J Med 2001; 345: 159-164.
6. Kauff ND, Satagopan JM, Robson ME, et al.: Riskreducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346: 1609-1615.
7. Rebbeck TR, Lynch HT, Neuhausen SL, et al.; Prevention and Observation of Surgical End Points Study Group: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346: 1616-1622.
8. Meindl A, Ditsch N, Kast K, et al.: Hereditary breast and ovarian cancer: new genes, new treatments, new concepts. Dtsch Arztebl Int 2011; 108: 323-330. Review.
9. Lakhani SR, Gusterson BA, Jacquemier J, Sloane JP, Anderson TJ, van de Vijver MJ, et al.: The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res 2000; 6: 782-789.
10. Lakhani SR, Reis-Filho JS, Fulford L, et al.; Breast Cancer Linkage Consortium: Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005: 11; 5175-5180.
11. Balleine RL, Provan PJ, Pupo GM, Pathmanathan N, Cummings M, Farshid G, et al.: Familial concordance of breast cancer pathology as an indicator of genotype in multiple-case families. Genes Chromosom Cancer 2010; 49: 1082-1094.
12. Bane AL, Pinnaduwage D, Colby S, Bull SB, O'Malley FP, Andrulis IL: Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors. Breast Cancer Res Treat 2009; 117: 183-191.
13. Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, et al.: Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998; 90: 1138-1145.
14. Robson ME, Chappuis PO, Satagopan J, et al.: A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/ BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 2004; 6: R8-R17.
15. Rakovitch E, Franssen E, Kim J, et al.: A comparison of risk perception and psychological morbidity in women with ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res Treat 2003; 77: 285-293.
16. Alexander NE, Ross J, Sumner W, et al.: The effect of an educational intervention on the perceived risk of breast cancer. J Gen Intern Med 1996; 11: 92-97.
17. Borzekowski DL, Guan Y, Smith KC, et al.: The Angelina effect: immediate reach grasp, and impact of going public. Genet Med 2013; 16: 516-521.
18. Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg): Krebs in Deutschland 2009/2010, 9. Ausgabe. Berlin, 2013.
19. Tutt A, Robson M, Garber JE, et al.: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376: 235-244.
20. Audeh MW, Carmichael J, Penson RT, et al.: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376: 245-251.
21. Tuttle TM, Habermann EB, Grund EH, et al.: Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol 2007; 25: 5203-5209.
22. Van Sprundel TC, Schmidt MK, Rookus MA, et al.: Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer 2005; 93: 287-292.
23. Kiely BE, Jenkins MA, McKinley JM, et al.: Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab). Breast Cancer Res Treat 2010; 120: 715-723.
24. Metcalfe K, Gershman S, Ghadirian P, et al.: Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ 2014; 348: g226.
25. Rhiem K, Engel C, Graeser M, et al.: The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study. Breast Cancer Res 20121; 4: R156.
26. Graeser MK, Engel C, Rhiem K, et al.: Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2009; 27: 5887-5892.
27. Bosse K, Rhiem K, Wappenschmidt B, et al.: Screening for ovarian cancer by trans-vaginal ultrasound and serum CA125 measurement in women with familial pre-disposition; a prospective cohort study. Gynecol Oncol 2006; 1033: 1077-1082